B
Bull
Bull · 25%IOBT
$2.41
Szenariopreis
$0.048
+0.023 (+48.61%)Zum Schluss
Loading chart…
- High
- 0.055
- Open
- 0.029
- VWAP
- 0.04
- Vol
- 481.59M
- Mkt Cap
- 77.08M
- Low
- 0.028
- Amount
- 20.98M
- EV/EBITDA, TTM
- 0.00
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
AI analysis of IO Biotech Inc (IOBT)
sellIO Biotech Inc (IOBT) is not a good buy for a beginner investor with a long-term strategy. The stock is experiencing significant price declines, has poor financial performance, and lacks positive catalysts. Analysts have downgraded the stock significantly, citing failed trials and capital constraints. There are no strong trading signals or recent influential purchases to support a buy decision.
Bewertungskennzahlen
The current forward P/E ratio for IO Biotech Inc (IOBT) is 0.00, compared to its 5-year average forward P/E of -1.41.
Alphio AI Price Scenarios for IOBT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IOBT
Event-Zeitleiste
News
4.501-30NewsfilterIO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction
4.001-27Yahoo FinancePiper Sandler Downgrades IO Biotech to Neutral Amid Strategic Review
2.001-23NASDAQ.COMBiotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
4.501-22NASDAQ.COMIO Biotech Evaluates Strategic Alternatives Amid $30.7M Cash Position
8.501-22BenzingaHigh Roller Technologies Inc Closes Direct Offering, Raises $25 Million
IOBT FAQ — answered by Alphio AI
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
IO Biotech Inc (IOBT) is not a good buy for a beginner investor with a long-term strategy. The stock is experiencing significant price declines, has poor financial performance, and lacks positive catalysts. Analysts have downgraded the stock significantly, citing failed trials and capital constraints. There are no strong trading signals or recent influential purchases to support a buy decision.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.